ArticleEuropean archives of psychiatry and clinical neuroscience2021
FMRI-based prediction of naltrexone response in alcohol use disorder: a replication study.
Article in European archives of psychiatry and clinical neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Functional magnetic response imaging predictors of alcohol use disorder treatment outcome: a systematic review.Alcohol and alcoholism (Oxford, Oxfordshire) · 2026Pooled it
- Parameter Space and Potential for Biomarker Development in 25 Years of fMRI Drug Cue Reactivity: A Systematic Review.JAMA psychiatry · 2024Pooled it
- Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial.Molecular psychiatry · 2025Trial
- The neurobiological cravings signature (NCS) as a predictive neuromarker of clinical outcomes in alcohol use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- The Impaired Response Inhibition and Salience Attribution Model of Drug Addiction: Recent Neuroimaging Evidence and Future Directions.Annual review of psychology · 2026Review
- The alcohol cue-exposure paradigm as a screening tool for alcohol use disorder medication development: A critical review.Alcohol, clinical & experimental research · 2025Review
- The Dopamine System in Mediating Alcohol Effects in Humans.Current topics in behavioral neurosciences · 2025Review
- High hopes? Precision psychedelic addiction medicine.Frontiers in psychiatry · 2025Review
- New Approaches to Addiction Treatment Based on Learning and Memory.Current topics in behavioral neurosciences · 2025Review
- Neuroimaging Biomarkers in Addiction.medRxiv : the preprint server for health sciences · 2024Article
- Exploratory study of associations between monetary reward anticipation brain responses and mu-opioid signalling in alcohol dependence, gambling disorder and healthy controls.Neuroimage. Reports · 2024Article
- The Role of fMRI in Drug Development: An Update.Advances in neurobiology · 2023Article
- Are we compulsively chasing rainbows?Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Pharmacological treatment in alcohol use disorder suffers from modest effect sizes. Efforts have been undertaken to identify patient characteristics that help to select individuals that benefit from pharmacological treatment. Previous studies indicated that neural alcohol cue-reactivity (CR) might provide a marker that identifies patients, which benefit from naltrexone treatment.We investigated the reproducibility of the association between ventral striatum (VS) activation and naltrexone (NTX) treatment response by analyzing data from a recent longitudinal clinical trial in N = 44 abstinent treatment-seeking alcohol-dependent patients. A follow-up was conducted over 3 months. We computed the percentage of significant voxels in VS and tested main effects and interactions with NTX treatment on relapse risk using Cox Regression models.We found a significant interaction effect between pre-treatment cue reactivity in the VS and NTX treatment on time to first heavy relapse (Hazard Ratio = 7.406, 95% CI 1.17-46.56, p = 0.033), such that the patient group with high VS activation (defined by a mean split) showed a significant medication effect (Hazard Ratio = 0.140, 95% CI 0.02-0.75, p = 0.022) with a number needed to treat of 3.4 [95% CI 2.413.5], while there was no significant effect in the group with low VS activation (Hazard Ratio = 0.726, p = 0.454).Thus, using an independent sample we replicated the previously described positive association between VS activation and NTX efficacy. Although our results should be considered cautiously in light of the small sample size, our results support the potential of neural alcohol CR as a tool for precision medicine approaches in alcohol dependence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.